Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash & Equivalents (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Cash & Equivalents for 10 consecutive years, with $54.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 0.74% year-over-year to $54.4 million, compared with a TTM value of $54.4 million through Sep 2025, up 0.74%, and an annual FY2024 reading of $33.8 million, down 21.52% over the prior year.
  • Cash & Equivalents was $54.4 million for Q3 2025 at Zevra Therapeutics, up from $47.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $132.3 million in Q2 2021 and bottomed at $33.8 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $68.1 million, with a median of $60.0 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents soared 3122.28% in 2021, then plummeted 46.72% in 2022.
  • Year by year, Cash & Equivalents stood at $112.3 million in 2021, then crashed by 41.73% to $65.5 million in 2022, then tumbled by 34.24% to $43.0 million in 2023, then fell by 21.52% to $33.8 million in 2024, then skyrocketed by 61.13% to $54.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for ZVRA at $54.4 million in Q3 2025, $47.7 million in Q2 2025, and $37.3 million in Q1 2025.